Recent News

• 09.16.2025 - Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement
• 09.16.2025 - Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement
• 09.10.2025 - Relmada Issues Mid-Year CEO Letter to Shareholders
• 09.10.2025 - Relmada Issues Mid-Year CEO Letter to Shareholders
• 08.07.2025 - Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC
• 08.07.2025 - Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC
• 07.31.2025 - Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
• 07.15.2025 - Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Recent Filings

• 09.16.2025 - EX-99.1 EX-99.1
• 09.16.2025 - 8-K Current report
• 09.10.2025 - EX-99.1 EX-99.1
• 09.10.2025 - 8-K Current report
• 09.02.2025 - 8-K Current report
• 08.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - 8-K Current report
• 08.07.2025 - EX-99.1 EX-99.1